Ken Alibek People who make biological weapons live with the risk that they will die by them. Ken Alibek found that out in a visceral way one Sunday evening in 1983 when a phone call to his home informed him that the tularemia plant he directed had a problem. When he arrived at the plant, Alibek went to inspect a room suspected of being contaminated by a leak from Zone 3, the interior area reserved for culture of tularemia bacteria. Entering alone and turning on the lights, he found himself stand
 Ken Alibek |
Tularemia is a plaguelike disease transmitted by bites from fleas, ticks, and flies. First described in the county of Tulare, in California, its potential as a weapon was recognized before World War II. America, Great Britain, and Canada once had tularemia battlefield weapons. Alibek was one of the few who knew Russia killed ...
When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.
In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.
Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.
Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST
Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.
Collaboration will bring next generation orchestration and modular automation to scientists worldwide
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
